Neuropeptide Research

Cerebrolysin Benefits and Side Effects: Research Data

What trials in dementia, stroke and brain injury reported, what Cochrane reviews concluded, which side effects were seen, and where Cerebrolysin stands with the FDA and EMA.

·
Fact-checked · Reviewed by Remy Research Editorial Board
Update History ▾
October 27, 2026: Initial publication, built from the 2023 and 2019 Cochrane reviews, primary trial papers and meta-analyses, the manufacturer’s prescribing information, Drugs@FDA, EMA’s centralised medicines data and FDA’s Category 2 page.
Research-use-only framing applied throughout in line with Remy editorial standards.
TL;DR — Research Summary

Cerebrolysin benefits have been studied in randomized trials in Alzheimer’s disease, vascular dementia, ischemic stroke and traumatic brain injury, and the results are mixed. It is a peptide preparation made from pig brain proteins by EVER Neuro Pharma in Austria, prescribed in many countries, and not approved by the US Food and Drug Administration.[1][2] Clinical trials and meta-analyses run by its investigators report gains in early stroke scores, global function and cognition; Cochrane reviews rated the vascular dementia evidence very low quality and found more non-fatal serious adverse events in acute stroke.[3][4][5]

This review sets out what each kind of study reported, separates cell and animal findings from human trials, lists the side effects seen in trials, and explains the FDA and EMA position. Remy Research supplies the compound for in-vitro laboratory research only, not for human or veterinary use.

Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

What Is Cerebrolysin?

Cerebrolysin is a mixture of low molecular weight peptides and amino acids derived from porcine brain; the Cochrane stroke review describes it as having potential neuroprotective properties and wide use in Russia, Eastern Europe, China and other Asian and post-Soviet countries.[5] A dementia review calls it a porcine brain-derived peptide preparation with pharmacodynamic properties similar to those of endogenous neurotrophic factors.[2] A 2024 case report describes it as derived from highly purified pig brain tissue.[6]

Its composition is about 25% low molecular weight peptides (under 10 kDa) and about 75% free amino acids, measured by total nitrogen content.[7] An independent mass-spectrometry analysis of one sample bought online identified 638 different peptides, mostly fragments of tubulin, actin and myelin basic protein, and found no fragments of the neurotrophic factors BDNF, NGF, GDNF or CNTF.[8] The marketing authorisation holder is EVER Neuro Pharma GmbH, which describes Cerebrolysin as a prescription medication; its prescribing information, based on the Austrian summary of product characteristics, lists cerebrovascular disorders as the indication: senile dementia of Alzheimer’s type, vascular dementia, stroke and craniocerebral trauma.[1]

How Cerebrolysin Works: Neurotrophic-Like Effects

The exact mechanism is not known, because the active components of the mixture have not been identified. The authors of the 2015 composition study suggested that its reported activity more likely comes from unknown “cryptic” peptides than from neurotrophic factor fragments.[8] Experimental studies point to three effects:

None of these effects has been measured directly in people, so they explain why Cerebrolysin was tested, not what it does in human brain tissue.

Potential Cerebrolysin Benefits Studied

The table lists each research area, what the main studies reported and the type of evidence. Most clinical studies were randomized and placebo controlled, but several were funded or co-authored by the manufacturer.[5][11]

Cerebrolysin Research Areas and Evidence
Research area What was reported Evidence type
Alzheimer’s disease Cognition better at four weeks, not at six months; global function better at both Meta-analysis of 6 RCTs
Vascular dementia Better cognition and global function; very low-certainty evidence Cochrane review, 6 RCTs
Acute ischemic stroke Little or no difference in death; better early NIHSS in pooled analyses Cochrane review; meta-analyses
Stroke rehabilitation Better arm function in CARS; no overall difference in a Korean trial Randomized trials
Traumatic brain injury Small-to-medium effect on combined outcomes at day 90 Meta-analysis of 2 RCTs
Neuron survival Less apoptosis; more neurogenesis Cell and animal studies

Sources: Alzheimer’s meta-analysis;[12] vascular dementia review;[4] stroke reviews and meta-analyses;[3][13] rehabilitation trials;[14][15] brain injury meta-analysis;[16] cell and animal work as cited above.

Alzheimer’s Disease: Double Blind Placebo Controlled Trials

In a 24-week double blind placebo controlled trial, 279 patients with mild to moderate Alzheimer’s disease were assigned to one of three Cerebrolysin arms or the placebo group. All three arms improved global function on the CIBIC+, but only one arm improved cognition on the ADAS-cog, and the share of patients reporting adverse events was similar across groups.[17] An earlier placebo-controlled study, which enrolled patients with Mini Mental State Examination scores of 14 to 25, reported better cognition, global impression and activities of daily living, with the effect still present at week 18.[18]

A meta-analysis of six randomized double blind placebo controlled trials, which searched the Cochrane Dementia Group database among others, found that Cerebrolysin was better than placebo for cognitive function at four weeks (95% CI −0.66 to −0.13 for the standardised mean difference) but not significantly at six months; global clinical change favoured it at both time points, and safety was comparable to placebo.[12] In a 197-patient trial that compared Cerebrolysin with donepezil and the combination, cognitive and functional changes did not differ significantly between the three groups.[19] A 2009 review of the clinical trials found positive effects on global measures and cognitive function in Alzheimer’s disease and vascular dementia, and called for longer-term trials.[2] No trial has tested cognitive enhancement in healthy people.

Vascular Dementia: Cognitive Decline and Global Function

Vascular dementia is the second most common cause of dementia, and evidence-based dementia treatment for it is still lacking.[4] In a 242-patient multicentre randomized double blind placebo trial, the ADAS-cog+ (the extended version of the cognitive subscale) improved by 10.6 points with Cerebrolysin and 4.4 points with placebo at week 24, and responder rates were higher.[20]

The 2019 Cochrane review pooled six trials with 597 participants. Combining MMSE and ADAS-cog+ data from three trials (420 people) favoured Cerebrolysin, and response rates on global measures were higher in two trials (379 participants), but the review authors rated the evidence very low quality, judged the included trials at high risk of bias and wrote that any benefit may be too small to be clinically meaningful. No study measured quality of life or caregiver burden, and the trials with funding details were supported by industry.[4]

Ischemic Stroke and Functional Recovery

The largest single trial, CASTA, randomized 1,070 patients with acute ischemic stroke in Asia. Its primary endpoint showed no significant difference between groups; a post hoc subgroup analysis of patients with NIHSS above 12 showed a favourable trend and lower 90-day mortality (10.5% vs 20.2%), which the authors said needs confirmation.[21]

Pooled analyses differ by who ran them. A meta-analysis of nine trials (1,879 stroke patients) by trial investigators found better early NIHSS scores, with a number needed to treat of 7.7, and safety comparable to placebo.[3] A 2025 meta-analysis of 14 trials by authors with no declared conflicts (2,884 patients) found a 1.39-point NIHSS benefit but no significant gain in functional independence and no difference in serious adverse events or mortality.[13] The 2023 review in the Cochrane Database of Systematic Reviews, in which seven trials compared Cerebrolysin or a Cerebrolysin-like agent with placebo or no treatment (1,773 participants), found little to no difference in all-cause death, and none of its included trials reported death or dependence at the end of follow-up.[5] In C-REGS2, a non-randomized study of 1,769 patients in 16 countries, functional recovery on the modified Rankin Scale favoured Cerebrolysin; several study authors reported honoraria from the manufacturer.[22]

Post Stroke Rehabilitation

In CARS, 208 post stroke patients also followed a standard rehabilitation programme; arm function at day 90 favoured Cerebrolysin, and the authors called the trial exploratory.[14] A pre-planned analysis of the two CARS trials (442 patients) agreed, with several authors reporting support from or employment by EVER Neuro Pharma.[11] In a Korean phase IV trial of 70 patients, motor function improved in both groups with no significant difference overall; only patients with severe impairment did better on Cerebrolysin.[15] A 2021 European guideline recommended Cerebrolysin for early neurorehabilitation after acute ischaemic stroke.[23]

Traumatic Brain Injury

The CAPTAIN series comprised two randomized placebo controlled trials of Cerebrolysin added to usual care after moderate to severe traumatic brain injury. Their prospective meta-analysis of 185 patients (mean age 45.3) found a small-to-medium effect on a combined set of functional and neuropsychological scales at days 30 and 90, with comparable safety and tolerability between groups.[16]

Cerebrolysin Side Effects and Adverse Events

Most trial reports describe Cerebrolysin as well tolerated, with adverse events similar to placebo.[17][12][14][16] The pooled data show these adverse effects and risks:

So the increased risk signal is specific: more non-fatal serious events in pooled acute stroke trials, not more deaths. The prescribing information lists three contraindications: hypersensitivity to a component, epilepsy and severe renal impairment. It refers to the summary of product characteristics for drug interactions, pregnancy and other warnings.[1]

Is Cerebrolysin Approved by the FDA?

Where Cerebrolysin stands as of October 28, 2026.
  • FDA. Not approved. EVER Pharma states that Cerebrolysin is not registered with the FDA and is not approved for sale or distribution in the United States, and the FDA’s Drugs@FDA database returns no Cerebrolysin product.[1][24]
  • EMA. Not authorised through the EU centralised procedure: EMA’s medicines dataset has no Cerebrolysin record.[25] Its prescribing information is based on the Austrian national summary of product characteristics, with EVER Neuro Pharma as marketing authorisation holder.[1]
  • Compounding. Cerebrolysin does not appear on FDA’s Category 2 list of bulk substances that may present significant safety risks.[26]
  • UAE. Remy Research supplies research grade Cerebrolysin for in-vitro laboratory research only, not for human or veterinary use. Research grade material is not the EVER Pharma medicinal product.

Cerebrolysin vs Semax

They are different substances. Cerebrolysin is a mixture of hundreds of pig-brain peptides plus free amino acids.[8] Semax is a single synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analog of ACTH(4-10); in rats it raised BDNF protein and TrkB activation in the hippocampus.[27] Both are linked to neurotrophic signalling, but Cerebrolysin has far more randomized trial data. See the Semax research review and Semax vs Selank.

What the Research Does Not Yet Show

Cerebrolysin for Laboratory Research

Remy Research supplies Cerebrolysin, intended for in-vitro research use only, as the Genovare Cerebrolysin 60mg AQ pen. The product page carries its batch testing details. For the full trial record, composition data and the 2025–2026 stroke studies, read the Cerebrolysin neuroprotective peptide research review; for a related nootropic compound, see the Dihexa research review.

Our Research Standards

This article prioritizes Cochrane systematic reviews, randomized trials and regulator records, labels each finding by evidence type, and notes where analyses were run or funded by the manufacturer. No therapeutic, dosing or administration guidance is given. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

Cerebrolysin FAQ

What are the benefits of Cerebrolysin?

Trials reported better global function and short-term cognition in Alzheimer’s disease, better cognition in vascular dementia (very low-certainty evidence), better early stroke scores in pooled analyses and a small effect after brain injury. Results are mixed.[12][4][3][16]

What are the side effects of Cerebrolysin?

Dizziness or vertigo was the most common adverse event in dementia trials. In acute stroke, Cochrane found more non-fatal serious adverse events, and rare anaphylaxis has been reported.[2][5][6]

Is Cerebrolysin FDA approved?

No. The manufacturer states it is not registered with the FDA or approved for sale in the United States, and Drugs@FDA has no Cerebrolysin product.[1][24]

Is Cerebrolysin approved by the EMA?

It has no EU centralised authorisation. Its prescribing information is based on the Austrian national summary of product characteristics.[25][1]

Is Cerebrolysin safe?

Trial safety was mostly comparable to placebo, but the 2023 Cochrane stroke review found more non-fatal serious adverse events with moderate certainty. Epilepsy and severe renal impairment are listed contraindications.[5][1]

What does Cerebrolysin do to the brain?

In animal and cell studies it reduced neuronal apoptosis, increased neurogenesis after stroke and restored nerve growth factor balance. These effects have not been measured directly in people.[7][10][9]

Is Semax the same as Cerebrolysin?

No. Semax is one synthetic seven-amino-acid peptide; Cerebrolysin is a pig-brain mixture of hundreds of peptides and free amino acids.[27][8]

What does the Cochrane review say about Cerebrolysin for stroke?

Seven trials showed little to no difference in all-cause death or in total serious adverse events, and an increase in non-fatal serious adverse events.[5]

Sources

  1. EVER Pharma. About Cerebrolysin: prescribing information (based on the Austrian summary of product characteristics: indications, contraindications, marketing authorisation holder EVER Neuro Pharma GmbH) and Notice to U.S. Visitors. Accessed October 28, 2026. cerebrolysin.com ↩
  2. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009;26(11):893-915. doi: 10.2165/11203320-000000000-00000 · PMID: 19848437 ↩
  3. Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. doi: 10.1007/s10072-017-3214-0 · PMID: 29248999 ↩
  4. Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900. doi: 10.1002/14651858.CD008900.pub3 · PMID: 31710397 ↩
  5. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026. doi: 10.1002/14651858.CD007026.pub7 · PMID: 37818733 ↩
  6. Trimmel H, Tauber W, Zikeli M. Life-threatening anaphylaxis due to Cerebrolysin. Case Rep Neurol Med. 2024;2024:2332908. doi: 10.1155/2024/2332908 · PMID: 39055722 ↩
  7. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm (Vienna). 2001;108(4):459-473. doi: 10.1007/s007020170067 · PMID: 11475013 ↩
  8. Gevaert B, D’Hondt M, Bracke N, et al. Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry. Drug Test Anal. 2015;7(9):835-842. doi: 10.1002/dta.1817 · PMID: 26017115 ↩
  9. Ubhi K, Rockenstein E, Vazquez-Roque R, et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res. 2013;91(2):167-177. doi: 10.1002/jnr.23142 · PMID: 23152192 ↩
  10. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88(15):3275-3281. doi: 10.1002/jnr.22495 · PMID: 20857512 ↩
  11. Guekht A, Vester J, Heiss WD, et al. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci. 2017;38(10):1761-1769. doi: 10.1007/s10072-017-3037-z · PMID: 28707130 ↩
  12. Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. doi: 10.1159/000377672 · PMID: 25832905 ↩
  13. Patel PN, Mangal D, Patel K. Safety and efficacy of Cerebrolysin for neurorecovery after acute ischemic stroke: a systematic review and meta-analysis of 14 randomized controlled trials. Cureus. 2025;17(8):e91054. doi: 10.7759/cureus.91054 · PMID: 41018475 ↩
  14. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-159. doi: 10.1161/STROKEAHA.115.009416 · PMID: 26564102 ↩
  15. Chang WH, Park CH, Kim DY, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurol. 2016;16:31. doi: 10.1186/s12883-016-0553-z · PMID: 26934986 ↩
  16. Vester JC, Buzoianu AD, Florian SI, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531-4541. doi: 10.1007/s10072-020-04974-6 · PMID: 33620612 ↩
  17. Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol. 2006;13(1):43-54. doi: 10.1111/j.1468-1331.2006.01222.x · PMID: 16420392 ↩
  18. Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002;(62):277-285. doi: 10.1007/978-3-7091-6139-5_25 · PMID: 12456070 ↩
  19. Alvarez XA, Cacabelos R, Sampedro C, et al. Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res. 2011;8(5):583-591. doi: 10.2174/156720511796391863 · PMID: 21679156 ↩
  20. Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-318. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.012 · PMID: 20656516 ↩
  21. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; CASTA Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. doi: 10.1161/STROKEAHA.111.628537 · PMID: 22282884 ↩
  22. Vosko MR, Sanak D, Do Y, et al. C-REGS2 - a multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke. Int J Stroke. 2025;20(9):1060-1070. doi: 10.1177/17474930251375439 · PMID: 40851188 ↩
  23. Beghi E, Binder H, Birle C, et al. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. Eur J Neurol. 2021;28(9):2831-2845. doi: 10.1111/ene.14936 · PMID: 34152062 ↩
  24. U.S. Food and Drug Administration. openFDA Drugs@FDA endpoint, search products.brand_name:CEREBROLYSIN returned “No matches found” (queried October 28, 2026). api.fda.gov ↩
  25. European Medicines Agency. Medicines evaluated through the centralised procedure (EPAR medicines dataset, data timestamp October 27, 2026): no record matching “cerebrolysin”. Searched October 28, 2026. ema.europa.eu ↩
  26. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of April 22, 2026. fda.gov ↩
  27. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. doi: 10.1016/j.brainres.2006.07.108 · PMID: 16996037 ↩

For catalog details, see the Genovare Cerebrolysin 60mg AQ pen. For editorial standards, continue to the editorial policy.

Research products mentioned in this article

Product Genovare Semax 25mg AQ Pen→ Product Genovare Selank + Semax 50mg AQ Pen→

Related Research

Catalog Genovare Cerebrolysin 60mg AQ Pen→ Research Cerebrolysin Neuroprotective Peptide Research→ Nootropic Semax Research Review→ Comparison Semax vs Selank→ Nootropic Dihexa Research Review→ Nootropic Selank Research Review→ Catalog Research Peptide Catalog→